Icon

Orenitram - (2.5 mg; Tablet, Extended Release)

Treprostinil United Therapeutic Corporation
2.5 mg; Tablet, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
Yes
******* ** *** ***** ** **** **** ** **** ******* ’*** (**** **, ****), ’ *** (**** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****), ’ *** (*** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****),’ *** (*** *, ****) *** ’*** (*** **, ****) *** *** ************ *********. ****** *** ****** ** ** ****** **** ********** *** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****. (*****://**************.**********.***/***-**********/********-****-****-****-************.***) ****** ************ *********** *** ******** ***************, *** ***** **** ******* *** *************** ** ***** **, ****
Orenitram Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
*** ****** ******* ******* ******* ******* ******* *** ********* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** *, **** ******* ********* ******** ** *** **, ****
*** ****** ** \ ** *** **, **** ******* **** ** ** ****
  1. *** **, **** : * **** ** ***** .
  2. *** **, **** : ******* ******** ****** ************ ***** *** **** ** **** ******* ’*** (**** **, ****), ’ *** (**** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****), ’ *** (*** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****),’ *** (*** *, ****) *** ’*** (*** **, ****).
  3. *** **, **** : ****** ************* ***** * **** ******* ******* ** ******** ***** ** **.
  4. *** **, **** : ********** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****.
  5. *** *, **** : ****** ************* ***** * **** ******* *** ****************
  6. *** **, **** : ****** ************* ********* ********** **** *** ***************. ** ****** ** *** * **********.

Orenitram - (0.25, 1 mg; Tablet ER)

Treprostinil United Therapeutic Corporation
0.25, 1 mg; Tablet ER
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
None None
None
No
****** ************* ***** * **** ******* *******. ********** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****. (*****://**************.**********.***/***-**********/********-****-****-****-************.***)
Orenitram Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** **, **** ******* ********* ******** ** *** **, ****
  1. *** **, **** : * **** ** *****.
  2. *** **, **** : ****** ************* ***** * **** ******* *******.
  3. *** **, **** : ********** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****.

Orenitram - (0.125, 5 mg; Tablet ER)

Treprostinil United Therapeutic Corporation
0.125, 5 mg; Tablet ER
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
None
No
* **** ** ***** ** ******* *******. ********* ** *********'* *** ******, ******** *** ****** *** ******* ** *** ****. (*****://**************.**********.***/***-**********/********-****-****-****-************.***)
Orenitram Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
** *******
  1. *** **, **** : * **** ** ***** ** ******* *******.
  2. *** *, **** : ******* ******** ********* ******** *** *** *** ********* *** **** ********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.